Editorial
Copyright ©The Author(s) 2017.
World J Biol Chem. May 26, 2017; 8(2): 102-107
Published online May 26, 2017. doi: 10.4331/wjbc.v8.i2.102
Table 1 Current status of selected type-2 methionine aminopeptidase inhibitors
NameType ofinhibitorPreclinical/clinical trails
Fumagillin[7-10]IrreversibleN/A
TNP-470[12,13]IrreversiblePhase I
PPI-2458[49]IrreversiblePhase I
CKD-732[61-64] (ZGN-433, beloranib)IrreversiblePhase II/III
SDX-7320[59,60]IrreversiblePhase II
Bengamides[65] (LAF389)ReversiblePhase I
2-Hydroxy-3-aminoamides[66]ReversiblePreclinical
Anthranilic acid sulfonamides[67]ReversiblePreclinical
Triazoles[68]ReversiblePreclinical
Indazoles[69]ReversiblePreclinical
Pyrazolo[4,3-b]indoles[70]ReversiblePreclinical